ClinicalTrials.gg
CompletedNCT00147134Updated Sep 22, 2016

A Trial to Evaluate Laparoscopic Versus Open Surgery for Colorectal Cancer

A Phase 3 interventional study of open colectomy and laparoscopic colectomy in Colorectal Cancer, sponsored by Haruhiko Fukuda. Completed at 26 sites in Japan. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-09-22.

Sponsored by Haruhiko Fukuda · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,050
Allocation
Randomized
Ages
20 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 174 studies in Colorectal Neoplasms with a site in Japan — 38 open to participants now, 67 under way, 14 of them phase 3. Colorectal Neoplasms · Japan.

Enrollment
6th of 160
1,050 · median 198
Started
2004
with 1 other
Phase 3
45 of 174
9 open now
Registered
1st of 174
by date

Among the 174 studies in Colorectal Neoplasms with a site in Japan, this one is the 6th largest by enrollment of the 160 interventional ones that give a count, is one of 2 that started in 2004, is one of 45 in phase 3, and was the 1st registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

38 of the 174 studies in Colorectal Neoplasms with a site in Japan are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 20 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 174 studies in Colorectal Neoplasms with a site in Japan, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate oncological outcome of patients for T3 and T4 colorectal cancer undergoing laparoscopic versus open surgery.

Read the detailed description

The benefits of laparoscopic surgery (LAP) in comparison to open surgery (OPEN) have been suggested with respect to decreased morbidity, decreased pain, faster recovery, and shorter hospital stay.1-4 However, the long-term survival of LAP for colorectal cancer is still unclear, especially for advanced colorectal cancer requiring extended lymphadenectomy. Thus, the investigators designed a study which investigates whether LAP is suitable for advanced colorectal cancer with respect to survival and post-operative morbidity.

03

Conditions studied

  • Colorectal Cancer

Keywords

  • colorectal cancer
  • laparoscopic surgery
  • randomized controlled trial
  • oncological outcome
04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. proven colorectal carcinoma
  2. Tumor located in the cecum, ascending colon, sigmoid colon, or rectosigmoid colon
  3. T3 or deeper lesion without involvement of other organs
  4. Without multiple lesion other than carcinoma in situ
  5. Cancer classified as N0-2 and M0, according to the TNM classification system
  6. Tumor size \< 8 cm
  7. No bowel obstruction
  8. Age 20 \< and > 75 years
  9. Sufficient organ function
  10. No history of gastrointestinal surgery
  11. No history of chemotherapy or radiotherapy
  12. Provided written

Exclusion criteria

Exclusion Criteria:

  1. Synchronous or metachronous (within 5 years) other than carcinoma in situ
  2. Severe pulmonary emphysema, interstitial pneumonitis, or ischemic heart disease
  3. Pregnant or lactating women
  4. Severe mental disease
  5. Continuous systemic therapy
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,050 participants (actual)

Study arms

  • Active comparator
    1

    Procedure/Surgery: open colectomy

    Procedure: open colectomy

  • Experimental
    2

    Procedure/Surgery: laparoscopic colectomy

    Procedure: laparoscopic colectomy

Interventions

  • Procedureopen colectomy

    Procedure/Surgery: open colectomy

  • Procedurelaparoscopic colectomy

    Procedure/Surgery: laparoscopic colectomy

06

What researchers measure

Primary outcomes

  1. Overall survival

    Time frame: During the study conduct

Secondary outcomes

  1. Relapse-free survival

    Time frame: During the study conduct

  2. Short-term clinical outcomes

    Time frame: time to 1st discharge after operation

  3. Adverse events

    Time frame: During the study conduct

  4. The proportion of conversion from LAP to OPEN

    Time frame: operation day

  5. The proportion of completion of LAP

    Time frame: operation day

07

Study locations

26 sites
  • Fujita Health University
    Toyoake,Kutsukake-cho,Dengakugakubo,1-98, Aichi 470-1192, Japan
  • National Cancer Center Hospital East
    Kashiwa,Kashiwanoha,6-5-1, Chiba 277-8577, Japan
  • Toho University Sakura Hospital
    Sakura,Shimoshidu,564-1, Chiba 285-8741, Japan
  • Jyuntendo Urayasu Hospital
    Urayasu,Tomioka,2-1-1, Chiba 279-0021, Japan
  • National Hospital Organization Shikoku Cancer Center
    Matsuyama,Horinouchi,13, Ehime 790-0007, Japan
  • Kurume University School of Medicine
    Kurume,Asahi-machi,67, Fukuoka 830-0011, Japan
  • Hiroshima University, School of Medicine
    Hiroshima,Minami-ku,Kasumi,1-2-3, Hiroshima 734-8551, Japan
  • Ishikawa Prefectual Central Hospital
    Kanazawa,Kuratsuki-Higashi,2-1, Ishikawa 920-8530, Japan
  • Teikyo University Hospital, Mizonokuchi
    Kawasaki,Takatsu-ku,Mizonokuchi,3-8-3, Kanagawa 213-8507, Japan
  • Kitasato University East Hospital
    Sagamihara,Asamizodai,2-1-1, Kanagawa 228-8520, Japan
  • Kitasato University School of Medichine
    Sagamihara,Kitasato,1-15-1, Kanagawa 228-8555, Japan
  • Showa University Northern Yokohama Hospital
    Yokohama,Tsuzuki-ku,Chigasakichuo,35-1, Kanagawa 224-8503, Japan
  • National Hospital Organization Kyoto Medical Center
    Kyoto,Fushimi-ku,Fukakusa,Mukaihata-cho,1-1, Kyoto 612-8555, Japan
  • Nagano Municipal Hospital
    Nagano,Tomitake,1333-1, Nagano 381-8551, Japan
  • Oita University Faculty of Medicine
    Yufu city,Hasama-machi, 1-1, Oita 879-5593, Japan
  • Osaka City General Hospital
    Osaka,Miyakojima-ku,Miyakojimahondori,2-13-22, Osaka 534-0021, Japan
  • Osaka University Graduate School of Medicine
    Suita,Yamada-oka,2-2, Osaka 565-0871, Japan
  • Osaka Medical College
    Takatsuki,Daigakucho,2-7, Osaka 569-0801, Japan
  • Omiya Medical Center, Jichi Medical School
    Saitama,Omiya-ku,Amanuma-cho,1-847, Saitama 330-8503, Japan
  • Sizuoka Cancer Center
    Sunto-gun,Nagaizumi-cho,Shimonagakubo,1007, Shizuoka 411-8777, Japan
  • Tokyo Medical and Dental University Hospital
    Bunkyo-ku,Yushima,1-5-45, Tokyo 113-8519, Japan
  • National Cancer Center Hospital
    Chuo-ku,Tsukiji,5-1-1, Tokyo 104-0045, Japan
  • Toho University Ohashi Hospital
    Meguro-ku,Ohashi,2-17-6, Tokyo 153-0044, Japan
  • Toranomon Hospital
    Minato-ku,Toranomon,2-2-2, Tokyo 105-8470, Japan
  • Kyorin University School of Medicine
    Mitaka,Shinkawa,6-20-2, Tokyo 181-8611, Japan
  • Keio University Hospital
    Shinjuku-ku,Shinanomachi,35, Tokyo 160-8582, Japan
08

References and documents

Publications

  • Saito S, Akagi T, Katayama H, Wakabayashi M, Inomata M, Yamamoto S, Ito M, Kinugasa Y, Egi H, Munakata Y, Kokuba Y, Bando H, Yasui M, Ikeda M, Nakajima K, Shida D, Kanemitsu Y, Kitano S; Colorectal Cancer Study Group of Japan Clinical Oncology Group. Identification of patient subgroups with unfavorable long-term outcomes associated with laparoscopic surgery in a randomized controlled trial comparing open and laparoscopic surgery for colon cancer (Japan Clinical Oncology Group Study JCOG0404). Ann Gastroenterol Surg. 2021 Aug 9;5(6):804-812. doi: 10.1002/ags3.12475. eCollection 2021 Nov. PubMed 34755012 ↗
  • Nishizawa Y, Akagi T, Inomata M, Katayama H, Mizusawa J, Yamamoto S, Ito M, Masaki T, Watanabe M, Shimada Y, Kitano S. Risk factors for early postoperative complications after D3 dissection for stage II or III colon cancer: Supplementary analysis of a multicenter randomized controlled trial in Japan (JCOG0404). Ann Gastroenterol Surg. 2019 Apr 4;3(3):310-317. doi: 10.1002/ags3.12246. eCollection 2019 May. PubMed 31131360 ↗
  • Fujii S, Akagi T, Inomata M, Katayama H, Mizusawa J, Ota M, Saito S, Kinugasa Y, Yamaguchi S, Sato T, Kitano S; Japan Clinical Oncology Group. Transitional impact of short- and long-term outcomes of a randomized controlled trial to evaluate laparoscopic versus open surgery for colorectal cancer from Japan Clinical Oncology Group Study JCOG0404. Ann Gastroenterol Surg. 2019 Mar 26;3(3):301-309. doi: 10.1002/ags3.12245. eCollection 2019 May. PubMed 31131359 ↗
  • Kitano S, Inomata M, Mizusawa J, Katayama H, Watanabe M, Yamamoto S, Ito M, Saito S, Fujii S, Konishi F, Saida Y, Hasegawa H, Akagi T, Sugihara K, Yamaguchi T, Masaki T, Fukunaga Y, Murata K, Okajima M, Moriya Y, Shimada Y. Survival outcomes following laparoscopic versus open D3 dissection for stage II or III colon cancer (JCOG0404): a phase 3, randomised controlled trial. Lancet Gastroenterol Hepatol. 2017 Apr;2(4):261-268. doi: 10.1016/S2468-1253(16)30207-2. Epub 2017 Feb 2. PubMed 28404155 ↗
  • Yamamoto S, Inomata M, Katayama H, Mizusawa J, Etoh T, Konishi F, Sugihara K, Watanabe M, Moriya Y, Kitano S; Japan Clinical Oncology Group Colorectal Cancer Study Group. Short-term surgical outcomes from a randomized controlled trial to evaluate laparoscopic and open D3 dissection for stage II/III colon cancer: Japan Clinical Oncology Group Study JCOG 0404. Ann Surg. 2014 Jul;260(1):23-30. doi: 10.1097/SLA.0000000000000499. PubMed 24509190 ↗

Related links

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2004, a primary completion of Mar 2014 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2005
First posted
Sep 7, 2005
Start
Nov 2004
Primary completionActual
Mar 2014
CompletionActual
Mar 2014
Last update
Sep 22, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00147134
Lead sponsor
Haruhiko Fukuda
Collaborators
Ministry of Health, Labour and Welfare, Japan
Responsible party
Haruhiko Fukuda (JCOG Data Center, Japan Clinical Oncology Group) — Sponsor-investigator
First posted
Sep 7, 2005
Start date
Nov 2004
Primary completion
Mar 2014
Completion
Mar 2014
Last update
Sep 22, 2016

Study contacts

Seigo Kitano, MD, PhD,FACS
study chair · Oita University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion